Wedge Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wedge Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,159	Closed	-$283K	–	588
2020 Q1	$283K	Buy	6,159 +751	+14%	+$37.7K	﹤0.01%	409
2019 Q4	$325K	Buy	5,408 +675	+14%	+$40.3K	﹤0.01%	465
2019 Q3	$268K	Buy	+4,733	New	+$266K	﹤0.01%	498
2018 Q3	–	Sell	-6,732	Closed	-$509K	–	600
2018 Q2	$509K	Buy	+6,732	New	+$424K	0.01%	459

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wedge Capital Management's EGRX Position: Q2 2020 in Review

Wedge Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 6,159 shares — an estimated $283K sold.

Wedge Capital Management first reported a position in EGRX in Q2 2018 and held it in 4 quarters. The position peaked at $509K in Q2 2018. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

Wedge Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Wedge Capital Management sold 6,159 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $283K.
Wedge Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
Wedge Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $509K in Q2 2018.
164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on Wedge Capital Management's 13F filing for Q2 2020, filed 10 Jul 2020.